

REFERENCES

Abrams J: Role of endothelial dysfunction in coronary artery disease. *Am J Cardiol.* 79(12b):2-9, 1997.

Alpert JS, Thygesen K, Antman E, et al: Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol.* 36:959-969, 2000.

American Heart Association: Heart Disease and Stroke Statistics-2005 Update. Dallas: American Heart Association. 2005.

Antman E: Decision making with cardiac troponin tests. *N Engl J Med.* 346:2079-2082, 2002.

Apple FS, Panteghini M, Ravkilde J, et al: Quality specifications for B-type natriuretic peptide assays. *Clin Chem.* 51:486-993, 2005.

Apple FS, Wu AH, Mair J, et al: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem.* 51:810-824, 2005.

Arakelyan A, Petrakova J, Hermanova Z, et al: Serum Levels of the MCP-1 Chemokine in Patients With Ischemic Stroke and Myocardial Infarction. *Mediators of Inflammation.* 3: 175–179, 2005.

Ardigo D, Themistocles LA, Stephen PF, Alan S, Hiatky M, Iribarren C, and Philip S: Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. *Physiol Genomics.* 31: 402-409, 2007

Aschoff L: Arteriosclerosis: A Survey of the Problem. New York: Macmillan. 1:1933.

Askari AT, Brennan ML, Zhou X, et al: Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. *J Exp Med.* 197:615-624, 2003.

Assman G, Schriewer H, Schmitz G, and Hagele EO: Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgC₁₂. *Chem.* 29: 12026-2027, 1976.

Aukrust P, Yndestad A, Smith C, Ueland T, and Gullestad L: Chemokines in cardiovascular risk prediction. *Thromb Haemost.* 97: 748-754, 2007.

Autiero M, Luttun A, Tjwa M, et al: Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. *J Thromb Haemost.* 1:1356-1370, 2003.

Azzazy HM, Pelser MM, Christenson RH, et al: Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. *Clin Chem.* 52:19-29, 2006.

Babuín L, Jaffe AS. Troponin et al: The biomarker of choice for the detection of cardiac injury. *CMAJ.* 173:1191-1202, 2005.

Baggiolini M, Loetscher P.; Chemokines in inflammation and immunity. *Immunol Today.* 21:418-20, 2000.

Bayes-Genis A, Conover CA, Overgaard MI, et al: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. *N Engl J Med.* 345:1022-1029, 2001.

Bender MedSystems GmbH Campus Vienna Biocenter 2: Enzyme-linked immunosorbent assay for quantitative detection of human MCP-1. BMS281 h MCP-1, 2006.

Bernd K, Bernd S, Rami A, et al: Monocyte Chemoattractant Protein-1 (MCP-1) Polymorphism And Outcome After Renal Transplantation. *J Am Soc Nephrol.* 13:2585-2589, 2002.

Blankenhorn DH, Nessim SA, Johnson RL, et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA.* 19(23):3233-3240, 1987.

Bock MD, Brogan GX, McCuskey, CF, et al: Evaluation of ck-mb isoform analysis for early diagnosis of myocardial infarction. *J Emerg Med.* 17:75-79, 1999.

Boring L, et al: Decreased lesion formation in CCR2 in mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature* 394:894-897, 1998.

Braunwald E, Antman EM, Beasley JW, et al: Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Report of the American College of

Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) ACC/AHA 2002.

Brennan, ML, Penn MS, Van Lente F, et al: Prognostic value of myeloperoxidase in patients with chest pain. *New Engl J Med.* 346:1595-1604, 2003.

Brogan GX Jr, Friedman S, McCuskey C, et al: Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the Emergency Department. *Ann Emerg Med.* 24:665-671, 1994.

Brown CE, Vishwanath RP, Aguilar B, et al: Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. *J Immunol.* 179(5):3332-41, 2007.

Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. *Science.* 232(4746):34-47, 1986.

Carl A, Ashwood ER and Bruns DE: Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. In *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.* 2: 903-967, 2006.

Chambless LE, Folsom AR, Davis V, et al: Risk factors for progression of common carotid atherosclerosis; the atherosclerosis risk in communities study, 1987-1998. *Epidemiol.* 155:38-47, 2002.

Charles Wadsworth et al. *Clinica Chimica Acta.* 138: 309-318, 1984.

Chew M, Zhou J, Daugherty A, et al: Thalidomide inhibits early atherogenesis in apoE-deficient mice. *APMIS Suppl.* 109:113-116, 2003.

Christodoulides N, Floriano P, Acosta S, et al: Toward the development of a lab-on-a-chip dual-function leukocyte and C-reactive protein analysis method for the assessment of inflammation and cardiac risk. *Clin Chem.* 51:2391-2395, 2005.

Conti E, Carrozza C, Capoluongo E, et al: Insulin-like growth factor-1 as a vascular protective factor. *Circulation.* 110:2260-2265, 2004.

Cosin-Sales J, Kaski JC, Christiansen M, et al: Relationship among pregnancy associated plasma protein-A levels, clinical characteristics and

coronary artery disease extent in patients with chronic stable angina. *Eur Heart.* 26:2093-2098, 2005.

Crowther MA, Ginsburg D, Grosser T: Pathogenesis of Atherosclerosis. *Hematology.* 436-441, 2005.

Danenberg HD, Szalai AJ, Swaminathan RV, et al: Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice. *Circulation.* 108(5):512-515. 2003

Danne O, Mockel M, Leuders C, et al: Prognostic implications of elevated whole blood choline levels in acute coronary syndrome. *Am J Cardiol.* 91:1060-1067, 2003.

Davies MJ, Woolif N, Rowles P, et al: Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. *Br Heart J.* 60:459, 1988.

Davies MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. *Circulation.* 82(3 Suppl):II38-II46, 1990 Sep.

De Lemos JA, McGuire DK, Drazner MH, et al: B-type natriuretic peptide in cardiovascular diseases. *Lancet.* 362:316-322, 2003.

De Lemos JA, Morrow DA, and Blazing MA: Serial measurement of monocyte chemoattractant protein -1 after acute coronary syndromes: results from A to Z trial. *J Am Coll Cardiol.* 50: 2117-2124, 2007.

Diego A, Themistocles LA, Stephen PF, et al: Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. *Physiol Genomics.* 31: 402-409, 2007.

Dietschy JM, Weeks LE and Delento JJ: Enzymatic assessment of free and estrified cholesterol levels using the oxygen electrode in a modified glucose analyzer. *Clin. Chem.. Acta;* 73: 407, 1976.

Dominik H, Matthias G, Thomas N, et al: A role for MCP-1/CCR2 in interstitial lung disease in children. *Respiratory Research.* 6:93, 2007.

Eikelboom JW, Lonn E, Genest J, Jr., et al: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. *Ann Intern Med.* 131(5):363-375, 1999.

Eriksson S, Halenius H, Pulkki I, et al: Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. *Clin Chem.* 51:839-847, 2005.

Faxon DP, Fuster V, Libby P et al: Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. *Circulation.* 109(21):2617-2625, 2004.

Fernandez E., Lolis E.: Structure, function, and inhibition of chemokines. *Annual Review of Pharmacology and Toxicology.* 42: 469-499, 2002.

Frangogiannis NG: The mechanistic basis of infarct healing. *Antioxid Redox signal.* 8: 1907-1939, 2006.

Friedwald WT, Levy RI and Fridrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. *Clin. Chem.* 18: 449-501, 1972.

Fritsma G: Laboratory results that predict arterial thrombosis. *Clinical Laboratory Science.* 14:262-268, 2001.

Garrido IP, Roy D, Calvinao R, et al: Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. *Am J Cardiol.* 93:88-90, 2004.

Gazi I, Lourida ES, Filippatos T, et al: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. *Clin Chem.* 51:2264-2273, 2005.

Georg AR, Peter F, Hubert H, et al: MCP-1 and MIP3- α serum levels in acute liver failure and molecular adsorbent recirculating system (MARS) treatment: A pilot study. *Scandinavian Journal of Gastroenterology.* 44: 745 - 751, 2009.

Gerszten RE, Garcia-Zepeda EA, Lim YC, et al: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature.* 22;398(6729):718-23, 1999.

Givertz MM, Braunwald E: Neurohormones in heart failure: Predicting outcomes, optimizing care. *Eur Heart J.* 25:281-282, 2004.

Goldman L, Cook EF, Brand DA, et al: A computer protocol to predict myocardial infarction in emergency department patients with chest pain. *N Engl J Med.* 318:797-803, 1988.

Gu L, et al: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptordeficient mice. *Mol Cell.* 2:275-281, 1998.

Gu L, Tseng SC, Rollins BJ.: Monocyte Chemoattractant Protein-1. *Chem Immunol.* 72:7-29, 1999.

Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation.* 106(6):679-684, 2002.

Hajime K., Sanshiro T., Yoshikazu T., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *Journal of Clinical Investigation.* 116(6): 1494-1505, 2006.

Hawiger J, Brass LF, Salzman EW, et al: Signal transduction and intracellular regulatory processes in platelets. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice.* 3rd ed. Philadelphia: JB Lippincott. 603-628, 1994.

Heeschen C, Hamm CW, Bruemmer J, et al: The chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment (CAPTURE) investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. *J Am Coll Cardiol.* 35:1535-1542, 2000.

Heeschen D, Dimmeler S, Fichtlscherer S, et al: Prognostic value of placental growth factor in patients with acute chest pain. *JAMA.* 291:435-441, 2004.

Holmsen H: Platelet secretion and energy metabolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice.* 3rd ed. Philadelphia: JB Lippincott. 524-545, 1994.

Kanda H, Tateya S, Tamori Y, et al: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J Clin Invest.* 116(6):1494-505, 2006.

Kemperman H, van den Berg M, Kirkels H, et al: B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. *Clin Chem.* 50:1670-1672, 2004.

Kockx MM, Cromheeke KM, Knaapen MW, et al: Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. *Arterioscler Thromb Vasc Biol.* 23(3):440-446, 2003.

Kolodgie FD, Gold HK, Burke AP, et al: Intraplaque hemorrhage and progression of coronary atheroma. *N Engl J Med.* 349(24):2316-2325, 2003.

Kutter D, Devaquet P, Vanderstocken G, et al: Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? *Acta Haematol.* 104:10-15, 2000.

Lange H, Suryapranata H, De Luca G, et al: Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med.* 350(26):2673-2681, 2004.

Lee TH, Juarez G, Cook EF, et al: Ruling out acute myocardial infarction. A prospective multi-center validation of a 12-hour strategy for patients at low risk. *N Engl J Med.* 324:1239-1246, 1991.

Li H, Cybulsky MI, Gimbrone MA, et al: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. *Arterioscler Thromb.* 13(2):197-204, 1993.

Libby P: Inflammation in atherosclerosis. *Nature* .420: 868-874,2002.

Lina S: Cigarette smoke, MCP-1 expression in vivo and atherogenesis. Tobacco related disease research program, 2006.

Lobo RA: Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. *Arch Intern Med.* 164:482-484, 2004.

Lynne A H, Trevor A B, Elaine K L, et al: Examination of MCP-1 (CCL2) partitioning and presentation during transendothelial leukocyte migration. *Laboratory Investigation.* 84: 81–90, 2004.

Magnussen M, Oleander O, Israelaaon B, et al: Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. *Diabetes Care.* 27:1929-1935, 2004.

Martin MJ, Hulley SB, Browner WS, Kuller LH, and Wentworth D: Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. *Lancet*. 25(8513): 933-936, 1986.

Martinovic I, Abegunewardene N, Seui M, and Vosseler M: Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease: *Circ J*. 69: 1484-1489, 2005.

Marx N, Imhof A, Froehlich J, et al: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. *Circulation*. 107(15):1954-1957, 2003.

Maus US, Henning H, Wenschuh K, et al: Role of endothelial MCP-1 in monocyte adhesion to inflamed human endothelium under physiological flow. *Am J Physiol Heart Circ Physiol*. 283: 2584–2591, 2002.

McDermott DH, Yang Q, Kathiresan S, et al: CCL2 Polymorphisms are Associated with Serum MCP-1 Levels and Myocardial Infarction in the Framingham Heart Study. *Circulation*. 112:1113-1120, 2005.

McGowan MW, Artiss JD and Strodtbrgh DR: A peroxidase-coupled method for the colorimetric determination of serum triglycerides. *Clin. Chem*. 29: 273-278, 1983.

Michael HL, Sabine M, Susanne K, et al: HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin dependent manner. *Journal of Cell Science*. 119: 4520-4530, 2006.

Michelle W C, Ronen A, Timothy A, et al: The C–C Chemokine MCP-1 Differentially Modulates the Avidity of b1 and b2 Integrins on T Lymphocytes. *Immunity*. 4: 179–187, February, 1996.

Mitchel AM, Brown MD, Menown IBA, et al: Novel protein markers of acute coronary syndrome complications in low-risk out patients: A systematic review of potential use in the emergency department. *Clin Chem*. 51:2005-2012, 2005.

Mockel M, Gerhardt W, Heller G Jr, et al: Validation of NACB and IFCC guidelines for the use of cardiac markers for early diagnosis and risk assessment inpatients with acute coronary syndromes. *Clin Chim Acta*. 303:167-179, 2001.

Moreno PR, Fuster V: The year in atherothrombosis. *J Am Coll Cardiol*. 44(11):2099-2110, 2004.

Moreno PR, Purushothaman KR, Fuster V, et al: Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. *Circulation*. 110(14):2032-2038, 2004.

Morten R, Morten BA, Paulo R, et al: IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with *M. tuberculosis* in a whole blood based T-cell assay. *BMC Research Notes*. 2:19, 2009.

Moser B, Loetscher P: Lymphocyte traffic control by chemokines. *Nat Immunol*. 2:123-128, 2001.

Mueller T, Gegenhuber A, Dieplinger B, et al: Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. *Clin Chem*. 51:2245-2251, 2005.

Namiki M, Kawashima S, and Yamashita T: Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. *Arterioscler Thromb Vase Biol*. 22: 115-120, 2002.

Nawsad S, Svane B, Hansson L, et al: Response of serum C-reactive protein to percutaneous coronary interventions has prognostic value. *Clin Chem*. 51:2124-2130, 2005.

Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. *Arteriosclerosis Thrombosis Vascular Biol*. 25:1102-1111, 2005.

Nishiyama K, Ogawa H, and Yasue H: Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. *Jpn Circ J*. 62: 710-712, 1998.

Norihiko S, Takashi W, Kengo F, et al: MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. *Journal of Leukocyte Biology*. Volume 79, March 2006.

NYHA: Revisions to Classification of Functional Capacity and Objective Assessment of Patients with Diseases of the Heart, newyork heart association, 1994.

Okamoto F, Sohmiya K, Ohkaru Y, et al: Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. *Clin Chem*. 38:231-238, 2000.

Packard CJ, O'Reilly DSJ, Caslake MJ, et al: Lipoprotein-associated phospholipase A₂ as an independent predictor of coronary heart disease. *N Engl J Med.* 343:1148-1155, 2000.

Pan Q, Yang X.H, Cheng YX, et al: Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. NF-κB in Ang II-induced MCP-1 production. *Brazilian Journal of Medical and Biological Research.* 42: 531-536, 2009.

Papayianni A, Alexopoulos E, and Giamalis P: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in hemodialysis patients: association with inflammation, dyslipidemia, and vascular events. *Nephrol Dial Transplant.* 17: 435- 441, 2002.

Parissis JT, Venetsanou KF, and Kalantzi MV: Serum profiles of granulocyte- macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. *Am J Cardiol.* 85: 777-779, 2000.

Pearson TA, Mensah GA, Alexander RW, et al: Markers of inflammation and cardiovascular disease : application to clinical and public health practice : a statement for health care professionals from the centers for disease control and prevention and the American heart association. *Circulation.* 107: 499-511, 2003.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, and Fadi YY: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for Disease Control and Prevention and the American Heart Association. *Circulation.* 107: 499-511, 2003.

Pelsters MM, Hanhoff T, Van der Voort D, et al: Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. *Clin Chem.* 50:1568-1575, 2004.

Prina LD, Decker WW, Weaver AL, et al: Outcome of patients with a final diagnosis of chest pain of undetermined origin admitted under the suspicion of acute coronary syndrome: a report for the Rochester Epidemiology Project. *Ann Emerg Med.* 43:59-67, 2004.

Proost P, Wuyts A, Van Damme J.: Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. *J Leukoc Biol.* 59:67-74, 1998.

Puleo PR, Meyer D, Wathen C, et al: Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out myocardial infarction. *N Engl J Med.* 331:561-566, 1994.

Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. *N Engl J Med.* 352: 20-28, 2005.

Ridker PM, Stampfer MJ, Rifai N et al: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA.* 285(19):2481-2485, 2001.

Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. *Circulation.* 109:1955-1959, 2004.

Roberto P, Andrea F, Eleonora G, et al: Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. *Experimental Gerontology.* 39(8): 1249-1252, 2004.

Rossi E, Biasucci LM, Citterio F, et al: Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: Predictive role of C-reactive protein. *Circulation.* 105:800-803, 2002.

Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* 288:321-333, 2002.

Rothenbacher D, Muller-Schoelze S, Harder C, Koenig W, and Kolb H: Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. *Arterioscler Thromb Vase Biol.* 26: 194-199, 2006.

Rothenbacher D, Muller-Scholze S, Herder C, et al: Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. *Arterioscler thromb vasc boil.* 26: 194-199, 2006.

Sachie A, Masaharu U, Chikaaki K, et al: Angiotensin II Enhances the Increase in MCP-1 Production Induced by TNF- from 3T3-L1 Preadipocytes. *Journal of Endocrinology.* 08-0363, 2009.

Schaefer EJ, Levy RI: Pathogenesis and management of lipoprotein disorders. *N Engl J Med.* 312(20):1300-1310, 1985.

Schechter AD, Rollins BJ, and Zhang YJ: Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. *J Biol Chem.* 272: 28568-28573, 1997.

Schiller K, Zillhardt M, Alley J, et al: Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model. *BMC Cancer.* 9:1-45, 2009.

Schonbeck U, Libby P: Inflammation, immunity, and HMGCoA reductase inhibitors: statins as antiinflammatory agents? *Circulation.* 109(21Suppl 1):II18-II26, 2004.

Schonbeck U, Sukhova GK, Shimizu K et al: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. *Proc Natl Acad Sci U S A.* 97(13):7458-7463, 2000.

Schonbeck U, Sukhova GK, Shimizu K, Mach F, and Libby P: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. *Proc Natl Acad Sci USA.* 97(13): 7458-7463, 2000.

Seino Y, et al: Expression of monocyte chemoattractant protein-1 in vascular tissue. *Cytokine.* 6:575-579, 1995.

Sheikine Y, Hansson GK.: Chemokines and atherosclerosis. *Ann Med.* 36: 98-118, 2004.

Silver MA, Maisel A, Yancy CW, et al: BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment, monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. *Congest Heart Fail.* 10:1-30, 2004.

Squire IB, Evans J, Ng LL, et al: Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohormonal parameters of left ventricular dysfunction. *J Card Fail.* 10:328-333, 2004.

Stamler J, Wentworth D, and Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 365,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). *Jama.* 256(20): 2823-2828, 1986.

Strok S, Baumann K, and Von Schacky C: The effect of 17beta-estradiol on MCP-1 serum levels in postmenopausal women. *Cardiovasc Res.* 53: 642-649, 2002.

Takaaki F, Yoshikazu Y, Mitsuho O, et al: Nonendothelial Mesenchymal Cell-Derived MCP-1 Is Required for FGF-2-Mediated Therapeutic Neovascularization Critical Role of the Inflammatory/Arteriogenic Pathway. *Arterioscler Thromb Vasc Biol.* 26:2483-2489, 2006.

Takeya M, et al: Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. *Human Pathol.* 5:534-539, 1993.

Taub DD: Chemokine-leukocyte interactions. The voodoo that they do so well. *Cytokine Growth Factor Rev.* 7:355-376, 1996.

The Lipid Research Clinics Coronary Primary Prevention Trial results I: Reduction in the incidence of coronary heart disease. *JAMA.* 251:351, 1984.

The Lipid Research Clinics Coronary Primary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA.* 251(3):365-374, 1984.

Tingting D, Jiao S, Ping Z, et al: Study on MCP-1 related to inflammation induced by biomaterials. *Biomed. Mater.* 4, 2009.

Tohru U, Nasser C, Saeed RK, et al: Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. *Nephrol Dial Transplant.* 18: 664-669, 2003.

Ulf J, Eveline S, Petra M, et al: Differential Expression of Mcp-1 and Its Receptor CCR2 in Glucose Primed Human Mesangial Cells. *Nephron.* 92:797-806, 2002.

Wagner W, Roderburg C, Wein F, et al: Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. *Stem Cells.* 25:2638-47, 2007.

Wald NJ, George L, Smith D, et al: Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy for the International Prenatal Research Group. *Br J Obstet Gynaecol.* 103:407-412, 1996.

Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med.* 350:655-663, 2004.

Warnick GR, Knopp RH and Fitzpatrick V: Estimating low density lipoprotein cholesterol by the friedwald equation is adequate for classifying patients on the basis of nationally recommended cut points. Clin. Chem. 36: 15-17, 1990.

Willems FF, Aengevaeren WR, Boers GH, et al: Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol. 40(4):766-772, 2002.

Wivott SD, deLemos JA, Morrow DA, et al: Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta. 346:119-128, 2004.

Wu AH, Apple FS, Gibler WB, et al: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Recommendations for the use of cardiac markers in coronary artery disease. Clin Chem. 45:1104-1121, 1999.

Wu AH: Markers for early detection of cardiac diseases. Scand J Clin Lab Invest. 65 (240):112-121, 2005.

Xia Y, Frangogiannis NG.: MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets. 6:101-107, 2007.

Yong-Jing G, Ling Z, Omar AS, et al: JNK-Induced MCP-1 Production in Spinal Cord Astrocytes Contributes to Central Sensitization and Neuropathic Pain. The Journal of Neuroscience. 29(13):4096-4108, 2009.

Young AC, Scapin G, Kromminga A, et al: Structural studies on human muscle fatty acid binding protein at 1.4 C5 resolution: binding interaction with three C18 fatty acids. Structure. 2:523-534, 1994.

Yusuf S, Wittes J, Friedman L, et al: Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 260(15):2259-2263, 1988.